IM12.{1-3,11} | Thyroid Dysfunction Foundations — Summary & Reflection

KEY TAKEAWAYS

Thyroid dysfunction is one of India's most prevalent endocrine disorders. Key epidemiological facts: hypothyroidism affects ~2–3% of the general population with female preponderance (6–8:1); Graves disease accounts for 70–80% of hyperthyroidism in iodine-replete populations; 263 million Indians live in iodine-deficient zones.

The HPT axis operates through TRH → TSH → thyroid hormone (T4/T3) synthesis → negative feedback. T4 is the main secretory product; T3 is the active form generated by peripheral deiodination. Only free (unbound) fractions are biologically active. In primary hypothyroidism: TSH rises, FT4 falls. In primary hyperthyroidism: TSH falls, FT4/FT3 rise. In secondary hypothyroidism (pituitary): both TSH and FT4 fall.

Thyroid hormone synthesis requires iodide (via NIS symporter), organification by TPO, and thyroglobulin as the scaffold — all steps TSH-regulated.

Hashimoto thyroiditis: CD8+ T-cell destruction + anti-TPO/anti-Tg antibodies → progressive hypothyroidism; HLA-DR4/DR5 association.
Graves disease: Stimulatory TRAb/TSI → constitutive TSH receptor activation → autonomous hyperthyroidism, diffuse goitre, ophthalmopathy; HLA-DR3 association.
IDD: Iodine deficiency → elevated TSH → compensatory goitre → if severe, hypothyroidism and cretinism.

RAIU interpretation: High diffuse = Graves; high focal = toxic adenoma; patchy high = TMNG; low + thyrotoxicosis = thyroiditis or factitious thyrotoxicosis. Contraindicated in pregnancy.

NIDDCP: Universal salt iodisation at ≥15 ppm (retail), monitoring by TGR + urinary iodine + neonatal TSH. Dramatically reduced endemic goitre and cretinism.

REFLECT

Consider the two patients from the opening hook — one with Graves disease, one with Hashimoto thyroiditis. Both have autoimmune thyroid disease; both have detectable anti-TPO antibodies. Yet one is profoundly hyperactive and the other hypothyroid. The distinction lies in a single molecular actor: the TRAb/TSI antibody, which drives autonomous stimulation in Graves disease and is absent in Hashimoto. This illustrates a broader principle in medicine: similar superficial features (autoimmunity, antibody positivity) can reflect fundamentally different mechanisms, and understanding mechanism is what guides targeted treatment. Reflect on this: if a patient's family member is found to have elevated anti-TPO antibodies on screening but is clinically well and has a normal TSH, what would you tell them? What follow-up would you recommend? How does the NIDDCP's iodine supplementation affect someone who already has subclinical Hashimoto thyroiditis? These are the questions that connect basic pathophysiology to individual patient care.